BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
BIOMARIN PHARMACEUTICAL INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$54.67−0.01 (-0.02%)
Close on Oct 19, 2026
- Market cap
- $10.63B
- P/E (TTM)
- 143.9
- Dividend yield
- –
Share price
+$1.38 (+2.59%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
BIOMARIN PHARMACEUTICAL INC grew revenue 11.2% to $3.41B over the twelve months to Jun 30, 2026. Operating income fell 80.8% to $149.26M, moving the operating margin from 25.3% to 4.4%. Free cash flow was $738.18M, up 6.2% from a year earlier.
Revenue
$3.41B
+11.2% vs. a year earlier
Operating income
$149.26M
-80.8% vs. a year earlier
Free cash flow
$738.18M
+6.2% vs. a year earlier
EPS, diluted
$0.38
-88.7% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $10.63B
- P/E ratio
- 143.9
- Price to sales
- 3.12
- Price to book
- 1.68
- Dividend yield
- –
- Free cash flow yield
- 6.94%
Fundamentals
- Revenue
- $3.41B
- Net income
- $72.97M
- EPS, diluted
- $0.38
- Free cash flow
- $738.18M
- Book value per share
- $32.51
- Diluted shares
- 194M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$3.41B+11.2% YoY
Gross profit
$2.59B+6.4% YoY
Operating income
$149.26M-80.8% YoY
Net income
$72.97M-88.9% YoY
EPS, diluted
$0.38-88.7% YoY
Free cash flow
$738.18M+6.2% YoY
Reported periodTrailing twelve months